{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:49:03Z","timestamp":1773701343282,"version":"3.50.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Breast cancer is the most common cancer in females. The inhibitors of cyclin-dependent kinase 4\/6 (CDK 4\/6) have revolutionized the treatment of\nbreast cancer. Palbociclib (Pal) is a highly potent CDK 4\/6 inhibitor. The side effects\nand poor absorption of Pal may influence efficiency. This prompted us to conjugate Pal\ndrug into the nanomaterial based on ZnO-ordered mesoporous carbon (ZnO-OMC) as a\nnanocarrier in drug delivery and investigate the anticancer activity of the Pal-conjugated\nZnO-OMC (Pal@ZnO-OMC) on breast cancer cells (MCF-7).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The ZnO-OMC composite was synthesized by the green method using Callicarpa plant extract, and Pal anticancer drug was loaded on the mentioned composite at\ndifferent pHs, times, and ratios of drug to composite. The loading of Pal on ZnO-OMC\ncomposite was investigated by FE-SEM, UV-Vis, Raman, and FT-IR spectroscopy methods. The controlled Pal release from Pal@ZnO-OMC hybrid was investigated at different pH values and times. Moreover, the cytotoxicity of Pal@ZnO-OMC was evaluated\non MCF-7 cells by MTT assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The results showed that ZnO-OMC is a highly efficient carrier with high loading of Pal, 82.5% at pH 7.0 for 3 h. The prepared Pal@ZnO-OMC exhibited favorable\nphysico-chemical characteristics such as the controlled and targeted release pattern\n(15.2% of Pal is released at pH 7.4 for 10 h, while 58.1% of Pal is released at pH 4.0)\nand efficient cytotoxicity (cell viability of 50.4% and 38.8% at 24 and 48 h, respectively). Free Pal was significantly less efficient (with half-maximal inhibitory concentration\n(IC50) of 151.9 \u03bcg\/mL for 48 h) than Pal@ZnO-OMC (with IC50 of 2.6 \u03bcg\/mL for 48 h).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The synergistic effects of Pal@ZnO-OMC nanoformulation due to the presence of ZnO in hybrid seemed to improve antiproliferation efficacies against MCF-7\ncells compared with the free Pal<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>All findings demonstrated that the designed Pal@ZnO-OMC hybrid can be\na potent nanoformulation for the treatment of MCF-7 breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298673403024251129174213","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:05:52Z","timestamp":1773299152000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Efficacy of Palbociclib-Conjugated ZnO-Ordered Mesoporous\nCarbon Nanohybrid against MCF-7 Breast Cancer Cell Line"],"prefix":"10.2174","volume":"33","author":[{"given":"Fatemeh Zahra Fallah","family":"Lajimi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Am.C., Islamic Azad University, Amol, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-3572","authenticated-orcid":true,"given":"Bahare","family":"Sabeti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Am.C., Islamic Azad University, Amol, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9477-248X","authenticated-orcid":true,"given":"Fereshteh","family":"Chekin","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Am.C.,Islamic Azad University, Amol, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahman Rahimi","family":"Esboei","sequence":"additional","affiliation":[{"name":"Department of Parasitology, Toxoplasmosis Research Center, Schoolof Medicine, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673403024251129174213","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/250573\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673403024251129174213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:05:56Z","timestamp":1773299156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/250573\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673403024251129174213","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}